Skip to main content
. 2023 Oct 9;29(10):2559–2569. doi: 10.1038/s41591-023-02598-9

Extended Data Fig. 8. Survival outcomes by detectable vs. undetectable ctDNA status at baseline.

Extended Data Fig. 8

(a) Patients with undetectable ctDNA at baseline (n = 10) had numerically longer PFS compared to patients with detectable ctDNA (n = 35, median PFS 8.31 vs 2.96 months). (b) Similar trends were noted for overall survival, such that patients with detectable ctDNA at baseline (n = 10) had numerically shorter OS compared to individuals with undetectable ctDNA at baseline (n = 35, median OS 10.94 vs. 16.89 months).